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Abstract Interleukin-1 (IL-1) signal transduction involves the
recruitment of the IL-1 receptor-associated kinase-1 (IRAK-1).
Subsequent signaling finally leads to nuclear translocation of
NFUB. We here show that the association and autophosphoryla-
tion of IRAK-1 was already detectable 30 s after IL-1
stimulation of ECV 304 cells. Significant levels of IRAK-1
accumulated in the nucleus 30 min after IL-1 stimulation shown
by Western blot analysis and confocal laser scanning microscopy.
Nuclear transfer of IRAK-1 upon IL-1 stimulation was
confirmed in the murine T cell line EL-4. This characterizes
nuclear localization of IRAK-1 as a possibly essential event in the
IL-1 signaling cascade. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
For long it remained an enigma how interleukin-1 (IL-1)
binding to its receptor at the cellular surface leads to gene
activation in the nucleus. The ¢rst step in unravelling IL-1
signaling was the discovery of a serine/threonine kinase that
becomes associated with the IL-1 receptor type I (IL-1R I)
upon IL-1 binding [1]. In the meantime, this IL-1 receptor-
associated kinase-1 (IRAK) has been cloned [2] and renamed
IRAK-1 after further kinases were found to bind to IL-1
receptors in various cells [3,4]. By now, the following key
events were reported to contribute to the formation of the
IL-1RI signaling complex: response to IL-1 depends on the
presence of the IL-1R accessory protein (IL-1R-AcP) [5,6]
which interacts with the IL-1RI [7,8] and also with IRAK-1
[8,9] ; IRAK-1 binding to IL-1RI and to IL-1R-AcP is sup-
ported by the adapter protein MyD88 [10,11] ; within the re-
ceptor complex IRAK-1 is autophosphorylated [2,12] and also
phosphorylates an endogenous substrate pp60 [1]. Down-
stream signaling by the activated IL-1 receptor complex is
mediated by a member of the TNF-associated factor family,
TRAF6 [13], and involves the activation of the TGF-L-acti-
vated kinase (TAK) [14], NFUB-inducing kinase (NIK) [15]
and IUB kinase (IKK) [16]. The latter enables activation of
NFUB and its translocation into the nucleus which appears to
be an essential consequence of cellular activation by IL-1.
Beyond this main signaling route cross-talk to MAP kinases
[17^19] and phosphatidyl-inositol-3 (PI3) kinase [20^22] path-
ways have been demonstrated.
The emerging view of IL-1-triggered phosphorylation cas-
cades is complemented by observations indicating receptor-
mediated tra⁄cking of IL-1 to the nucleus. Both, IL-1 [23^
27] and the IL-1RI [26,28], as well as the receptor-associated
PI3-kinase [29] were detected in the nucleus upon IL-1 stim-
ulation. The translocation of receptor-bound IL-1 was
claimed to contribute to or to be essential for gene transacti-
vation [25,26]. The potential relevance of IL-1 tra⁄cking is
further supported by (i) the detection of two proteins with
nucleic acid binding sequence characteristics in the immune-
precipitated IL-1RI complex [30], (ii) the association of the
chaperone-type HSP74 (Mortalin) [30] with the IL-1 receptor,
and (iii) putative nuclear localization sequences (NLS) in the
cytoplasmic domain of the IL-1RI [26,31], in the PI3-kinase
[29], in mature IL-1L [24] and in the precursor but not the
mature form of IL-1K [32,33]. It is not clear, however,
whether the nuclear localization of IL-1RI and IL-1L are es-
sential for signaling [26,34] whereas it regulates IL-1K precur-
sor-mediated endothelial cell functions [33,35].
We thus looked whether other components of the IL-1RI
complex might undergo cellular tra⁄cking. We found that
IRAK-1 was translocated into the nucleus upon IL-1 stimu-
lation of ECV 304 and EL-4 cells. It there appeared synchro-
nously with activated NFUB lending support to the idea of a
potential synergy of NFUB activation and receptor complex
tra⁄cking.
2. Materials and methods
2.1. Cell culture and stimulation
ECV 304, described as a human umbilical cord vein endothelial cell
line, was recently reported to be rather a derivative of the human
epithelial urinary bladder line T24 [36]. Despite this uncertainty, the
cell line remained in this study because the cellular response to IL-1
investigated was not considered speci¢c for endothelial cells. ECV 304
cells were grown in medium M199 EARLE supplemented with 5%
FCS, 0.68 mM L-glutamine, 0.22% NaHCO3, 5 mM HEPES, 50 U/ml
penicillin^streptomycin. EL-4 cells were cultured in RPMI 1640, 2 mM
L-glutamine and 5% FCS. Both cell lines were washed two times with
medium lacking FCS and then treated with or without 10 ng/ml re-
combinant human (rh)IL-1L (GBF, Braunschweig, Germany) at 37‡C
for up to 2 h at a cell density of 5U106 cells/ml.
2.2. In vitro kinase assay
After stimulation with IL-1, cells were washed three times with PBS
and lysed in 1% Brij98 (Sigma), 50 mM NaCl, 50 mM Tris, pH 7.4 at
4‡C for 1 h. Postnuclear supernatants of 2U107 cells were incubated
with 1 Wg anti-IL-1-RI-antibody (Pharmingen) and 50 Wl of a protein
G-Sepharose slurry at 4‡C overnight. Immunoprecipitates were
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washed three times in lysis bu¡er and three times in kinase bu¡er
consisting of 100 mM NaCl, 20 mM HEPES, 5 mM MnCl2, 5 mM
MgCl2, pH 6.5. The in vitro kinase assay was performed by adding
2 WCi 32P-Q-ATP for 10 min at room temperature. The kinase reaction
was stopped with kinase bu¡er containing 20 mM EDTA, samples
washed ¢ve times with the same bu¡er and proteins separated from
antibody and protein G-Sepharose by boiling for 5 min in Laemmli
bu¡er. Sepharose was removed by centrifugation and proteins sepa-
rated on 5^7.5% SDS^PAGE gradient gels. Dried gels were autoradio-
graphed on Kodak X-Omat ¢lms.
2.3. Nuclear extracts
ECV and EL-4 cells were washed in PBS and resuspended in PBS
containing 5 mM MgCl2, 1 mM PMSF, 1 mM benzamidine^HCl,
1 Wg/ml leupeptin, 1 Wg/ml pepstatin and the protease-inhibitor-cock-
tail complete1 (Roche, Mannheim, Germany). Pottered cells were
centrifuged for 10 min at 600Ug. Pellets containing intact nuclei
were washed in PBS with protease inhibitors, resuspended in 20
mM Tris, pH 7.5, 250 mM sucrose, 10 mM MgCl2, and further
puri¢ed by ultracentrifugation (80 000Ug, 1 h) through 30% sucrose
in the same bu¡er. Pellets were washed three times with PBS and
nuclear protein was extracted with high salt bu¡er (20 mM HEPES,
pH 7.9, 400 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM DTT,
1 mM PMSF). IRAK-1 was precipitated from 50 Wg nuclear protein
by incubation with 0.5 Wl anti-IRAK-1-antiserum (C-terminal, aa
699^712, Calbiochem) and 50 Wl of a protein G-Sepharose slurry at
4‡C overnight. Samples were washed six times with 50 mM NaCl,
50 mM Tris, pH 7.4 and prepared for gel separation as described
above. 10% SDS^PAGE gels were immunoblotted to nitrocellulose.
2.4. Western blotting
Western blot analysis was performed with an anti-IRAK-1-antise-
rum (1:4000, C-terminal, aa 699^712, Calbiochem) or an anti-IRAK-
1-antibody (1 Wg/ml, aa 440^712, Santa Cruz) as indicated. As second
antibody a POD-conjugated goat anti-rabbit antibody (Roche,
1:3000) was used. Bands were made visible by chemiluminescence
imaging with the Fuji LAS1000-CCD-camera system.
2.5. Immuno£uorescence
ECV 304 cells were seeded for adherence in 24 well plates overnight.
PBS washed cells were permeabilized with ice cold acetone/methanol
(1+1, 2 min), washed, blocked with 2% swine serum and incubated
overnight with anti-IRAK-1-antibody (C-terminal, aa 440^712, 400
ng/ml, Santa Cruz). After washing, TRITC-conjugated swine anti-
rabbit antibody (1:100, DAKO) was added for 1 h at room temper-
ature. Hoechst 33258 (1 Wg/ml) was added for 30 min to visualize cell
nuclei. Washed cells were embedded in glycerol^gelatine and analyzed
using a Zeiss Laser Scan Inverted 410 Axiovert microscope with an
argon^krypton laser. Optical sections were taken every 0.2 Wm
(512U512 pixel images).
3. Results
3.1. Transient recruitment of IRAK-1 to the IL-1RI
Already 30 s after stimulation of ECV 304 cells with IL-1,
IRAK-1 was associated with the IL-1RI as observed by co-
precipitation with the IL-1RI antibody and immunostaining
with an IRAK-1 antibody (Fig. 1A). In the absence of IL-1 no
IRAK-1 was found associated with the receptor. IRAK-1 mi-
grated at a molecular weight of about 80 kDa (lower band)
and as a di¡use band at a molecular range of 85^110 kDa
which is characteristic for the phosphorylated form. The max-
imum amount was coprecipitated after 1 min, then IRAK-1
disappeared and was hardly detectable after 15 min of IL-1
stimulation.
3.2. Transient phosphorylation of IRAK-1 associated to the
IL-1RI
IL-1-induced phosphorylation of IRAK-1 in ECV 304 cells
was estimated by an in vitro kinase assay in immunoprecipi-
tates of postnuclear supernatants (Fig. 1B). While background
phosphorylation in untreated cells was barely detectable (Fig.
1B, lane 1), phosphorylation of IRAK-1 became detectable
30 s after IL-1 stimulation as a di¡use band with an apparent
molecular weight of about 80^100 kDa (Fig. 1B, lane 2) and
disappeared after 15 min. Phosphorylation of IRAK-1 thus
showed the same kinetics as its recruitment to the receptor
indicating that once bound to the receptor, IRAK-1 becomes
phosphorylated either via autophosphorylation or by another
associated kinase. The latter idea is supported by the fact that
phosphorylation of p60 did not change when IRAK-1 was
released from the receptor (Fig. 1B).
3.3. Detection of IRAK-1 in nuclear protein extracts by
Western blot analysis
60 min after IL-1 stimulation association of IRAK-1 to the
receptor was neither detectable by the in vitro kinase assay
nor by Western blot analysis (not shown). Also, no IRAK-1
was detected in postnuclear supernatants (not shown). This
indicates either degradation or changed subcellular distribu-
tion of IRAK-1. We, therefore, investigated whether it could
have been transported into the nucleus in ECV 304 cells and,
Fig. 1. Transient coprecipitation of IRAK-1 with the IL-1-RI in ECV 304 cells. Cells were stimulated with IL-1 for the times indicated. Super-
natants of Brij98 lysates were immunoprecipitated with an anti-IL-1-RI-antibody. A: Washed samples were loaded onto a 5^7.5% SDS^PAGE
gradient gel. Western blot detection was performed with an IRAK-1-antibody (1 Wg/ml, Santa Cruz) and a POD-conjugated goat anti-rabbit
antibody (Roche, 1:3000). H indicates the heavy chain of the antibody used for immunoprecipitation. B: Immunoprecipitates were used for the
in vitro kinase assay described in Section 2. Shown is an autoradiograph of a 5^7.5% SDS^PAGE gradient gel.
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in addition, in EL-4 cells. Purity of nuclear extracts was
controlled by measurement of the marker enzymes lactate
dehydrogenase, glucose-6-phosphate-dehydrogenase, phos-
phoglucose isomerase (cytosol), cytochrome c-oxidase (mito-
chondria), alkaline phosphatase (membranes) and by estima-
tion of the DNA content at 600 nm following Dische et al.
[37]. All enzymes were found to be less than 8% in nuclear
extracts compared to their native localization sites.
IL-1-stimulated phosphorylation was not observed in in
vitro kinase assays with IRAK-1 precipitated from nuclear
extracts (not shown). In contrast, IRAK-1 protein, which
was negligible in nuclear extracts of control cells (Fig. 2A,B,
lane 1), increased signi¢cantly following 30 and 60 min of IL-
1 stimulation in ECV 304 cells or following 1 and 2 h in EL-4
cells (Fig. 2A,B, lanes 2 and 3), respectively.
3.4. Detection of IRAK-1 in the nucleus by laser scanning
microscopy
To verify the Western blot data of nuclear located IRAK-1
we performed laser scanning microscopy. IRAK-1 was located
in the cytosol of unstimulated ECV 304 cells (Fig. 3A, left
part). Following 30 min of IL-1 stimulation IRAK-1 was
detected at the nuclear membrane and as a bulk being trans-
ported through the nuclear membrane into the nucleus (Fig.
3A, middle part). After 1 h of IL-1 stimulation the amount of
IRAK-1 in the cytosol was signi¢cantly diminished and most
of IRAK-1 was located in the nucleus in a condensed form
(Fig. 3A, right part). Cells which were incubated with the
second antibody only showed unspeci¢c staining not signi¢-
cant for IRAK-1 (Fig. 3A, insert).
3.5. Nuclear localization of IRAK-1 occurs simultaneously with
NFUB
Translocation of NFUB was monitored during the same
time scale of IL-1 stimulation (Fig. 3B). Prior to IL-1,
NFUB was only present in the cytosol (Fig. 3B, left part).
30 min after IL-1 stimulation most of the NFUB protein could
be localized at the nuclear membrane and in the nucleus of
ECV 304 cells (Fig. 3B, middle part). After 1 h of IL-1 stim-
ulation NFUB was signi¢cantly decreased in the cytosol, in-
stead it was found in a condensed form in the nucleus as was
observed for IRAK-1 (Fig. 3B, right part).
4. Discussion
We here demonstrate the accumulation of IRAK-1 in the
nucleus in response to IL-1. The data, obtained by two di¡er-
ent methods and with two di¡erent cell lines indicate that
translocation of IRAK-1 might be an essential part in the
signaling cascade of IL-1. Nuclear translocation of IL-1RI-
associated proteins so far has not been studied in detail and
only a few data on IL-1 and IL-1RI translocation are avail-
able. Internalization of the IL-1 receptor upon IL-1 binding
was ¢rst shown in 1987 [38]. Whereas the receptor was found
to be downregulated, IL-1 was not degraded after internal-
ization but rather accumulated in the nuclei of EL-4 cells 2^4
h after stimulation suggesting a so far unexplained function of
IL-1 in the nucleus [38]. Although the IL-1-loaded IL-1 re-
ceptor was shown to unspeci¢cally bind to DNA [28], a postu-
lated nuclear IL-1 receptor has never been identi¢ed. It is even
controversially discussed whether internalization and nuclear
localization of IL-1 are required to trigger signals at all [25^
27]. It might thus not be IL-1 itself but other proteins from
the IL-1RI complex which must be transported into the nu-
cleus for function.
The recent ¢nding that upon stimulation with IL-1 PI3-ki-
nase is ¢rst recruited to the IL-1RI [20,21] or AcP [22] and
then transported into the nucleus [29] demonstrates (i) that
multiple kinases act in the IL-1RI complex and (ii) that cel-
lular tra⁄cking might be equally involved. Translocation of
PI3-kinase into the nucleus occurred within 15 min and was
transient [29]. It could be prevented by a point mutation in
the IL-1RI binding site (Y479F) for the p85 subunit of PI3-
kinase and by PI3-kinase inhibitors [29]. Thus binding to the
IL-1RI as well as kinase activity is required for nuclear trans-
localization of PI3-kinase. Whether the kinase activity of
IRAK-1 is similarly required for nuclear localization is not
known. Interestingly, HEK-293 cells overexpressing a kinase-
defective mutant of IRAK-1 (D340N) were still able to acti-
vate NFUB following IL-1 stimulation [39]. Overexpression of
Fig. 2. Immunostaining of IRAK-1 in nuclear extracts of IL-1 stimulated cells. ECV 304 (A) and EL-4 (B) cells were preincubated with or
without IL-1L (10 ng/ml) for the times indicated. IRAK-1 was precipitated from 50 Wg nuclear extracts with an anti-IRAK-1-antiserum (C-ter-
minal, aa 699^712, Calbiochem), the precipitate separated on a 10% SDS gel and immunoblotted to nitrocellulose membranes. IRAK-1 was
made visible with a serum dilution of 1:4000, a POD-conjugated second antibody and the Fuji LAS1000-CCD-camera system. H marks the un-
speci¢c reaction of the heavy chain of the antiserum. For further experimental details see Section 2.
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a second kinase-inactive IRAK-1 mutant (K239S) in EL-4
cells did not inhibit IL-1-induced activation of c-Jun N-termi-
nal kinase, NFUB and IL-2 production [40]. It was therefore
suggested that the kinase activity of IRAK-1 is not required
for downstream signaling at all. That we did not ¢nd any
IRAK-1 activity in the nuclei of IL-1-stimulated cells (not
shown) might support this idea.
Nuclear localization of proteins larger than 45 kDa requires
sorting sequences, called NLS. A protein, called importin,
directly binds to such sequences, thereby driving transport
of the respective protein into the nucleus [41]. Such transport
is energy-dependent and utilizes the GDP-bound small
GTPase Ran [42]. A nuclear localization signal is present in
the human IRAK-1 at aa 503^508 (RRXKRR) but mouse
IRAK-1 lacks such a signal. Thus, IRAK-1 most probably
is not transported as such, it is rather supported by other
sorting proteins. Possible candidates might be the receptor,
as suggested for the transport for IL-1, or mortalin, the chap-
Fig. 3. Subcellular distribution of IRAK-1 and NFUB in IL-1-stimulated ECV 304 cells. ECV 304 cells were preincubated with or without IL-
1L (10 ng/ml) for the times indicated. Permeabilized cells were incubated with an anti-IRAK-1-antibody (A), or an anti-NFUBp65-antibody (B)
and followed by a TRITC-conjugated swine anti-rabbit-antibody. Hoechst 33258 was used to visualize cell nuclei. Cells were analyzed using a
Zeiss Laser Scan Inverted 410 Axiovert microscope with an argon^krypton laser. Sections through the center of the cells are shown (512U512
pixel images). Red color shows £uorescence of IRAK-1, green £uorescence shows nuclei (changed from blue). Bars indicate 5 Wm.
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erone-type heat shock protein 74, which has been found to be
associated with the IL-1RI complex [30]. A typical nuclear
import sequence, KXRRR is present in IL-1R and IL-1L
[24] and deletion of such nuclear localization signals in the
IL-1RI prevented the induction of IL-2 by IL-1 [25] in human
¢broblasts, but did not a¡ect IL-1-mediated IL-8 induction in
the human Jurkat T cell line transfected with the mouse IL-
1RI [34]. Since the amino acids identi¢ed as essential for sig-
nal transduction are di¡erent in human and mouse IL-1RI (aa
477^527 for human [25] versus aa 364^474 for mouse [34] IL-
1RI) the failure to block IL-8 gene activation might be due to
an impairment of the interactions of the murine IL-1RI with
human components of the IL-1RI signaling complex. The
essential region in the IL-1RI now is known as the so-called
TIR domain (Toll/IL-1-receptor domain) [31]. There MyD88
binds with its own TIR domain thereby presenting the death
domain for the interaction with IRAK-1 [11]. Thus, the dele-
tion of diverse NLSs equally resulted in the deletion of the
interaction site for IRAK-1 which might explain the observed
e¡ects.
IRAK-1 is relevant to NFUB. Mutations in the cytoplasmic
domain of IL-1RI (aa 508^521) prevented coprecipitation of
IRAK-1 and IL-1RI and blocked NFUB activation [43]. A
concurrent loss of IRAK-1 and NFUB activation was ob-
served by deletion of a C-terminal part in the cytoplasmic
domain of IL-1RI, called box 3 spanning aa 467^515 [44].
Finally, cells made de¢cient in IRAK-1 by gene targeting
are no longer able to activate NFUB in response to IL-1
[45], whereas the response to TNF remained. In summary,
genetic manipulations a¡ecting IRAK-1 association to the
receptor a¡ect NFUB activation while kinase activity does
not. The mechanism linking receptor association and trans-
cellular tra⁄cking of IRAK-1 to NFUB activation is far from
being understood. In a recent study [12] a transient recruit-
ment of IRAK-1 to the IL-1RI in MRC-5 lung ¢broblasts was
shown. The disappearance of IRAK-1 from the receptor cor-
related with the loss of IUB and could be delayed but not
abolished by proteasome inhibition. This was interpreted as
proteasomal degradation of IRAK-1. A redistribution of
IRAK-1 into subcellular compartments, however, was not
shown. Based on the data presented here, the observed decline
of IRAK-1 equally complies with alternative explanations.
IRAK-1 translocation to the nucleus (i) could occur in asso-
ciation with NFUB, (ii) it could be supported by components
of the NFUB system, or (iii) could facilitate the transport of
NFUB itself. An inhibition of IUB degradation would then
prevent both translocation of NFUB and of IRAK-1.
The function of nuclear IRAK-1 remains speculative. The
questioned relevance of IRAK-1 kinase activity (see above)
and the failure to detect any enhanced nuclear kinase activity
after import of IRAK-1, however, clearly point to a distinct
role of the translocated IRAK-1 in IL-1 signaling that com-
plements the established IL-1-dependent cytosolic cascade of
phosphorylations. The pleiotropic e¡ects of IL-1 may require
a broad arsenal of signaling pathways comprising the activa-
tion of diverse kinases and cellular tra⁄cking of components
of the IL-1RI complex that exert their action at the nucleus
level by enabling or modulating the e⁄cacy of transcription
factors.
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